口服巴瑞替尼治疗白癜风的再色素沉着 - Suppr

Repigmentation of vitiligo with oral baricitinib.

作者信息

Mumford Blake P, Gibson Andrew, Chong Alvin H

机构信息

Skin Health Institute, Carlton, Victoria, Australia.

Melbourne Rheumatology Group, Malvern, Victoria, Australia.

出版信息

Australas J Dermatol. 2020 Nov;61(4):374-376. doi: 10.1111/ajd.13348. Epub 2020 Jun 3.

DOI:10.1111/ajd.13348

PMID:32491188

Abstract

摘要

相似文献

Repigmentation of vitiligo with oral baricitinib.

Australas J Dermatol. 2020 Nov;61(4):374-376. doi: 10.1111/ajd.13348. Epub 2020 Jun 3.

Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome.

Clin Exp Dermatol. 2021 Oct;46(7):1330-1332. doi: 10.1111/ced.14712. Epub 2021 Jun 4.

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.

Ann Rheum Dis. 2022 Mar;81(3):335-343. doi: 10.1136/annrheumdis-2021-221276. Epub 2021 Oct 27.

Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report.

Rheumatology (Oxford). 2021 Apr 6;60(4):e122-e123. doi: 10.1093/rheumatology/keaa521.

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.

RMD Open. 2020 Feb;6(1). doi: 10.1136/rmdopen-2019-001095.

Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.

Arthritis Care Res (Hoboken). 2021 Apr;73(4):481-488. doi: 10.1002/acr.24144.

Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.

Rheumatology (Oxford). 2021 Sep 1;60(9):4048-4054. doi: 10.1093/rheumatology/keaa858.

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.

Ann Rheum Dis. 2021 Sep;80(9):1130-1136. doi: 10.1136/annrheumdis-2020-219699. Epub 2021 Apr 7.

Baricitinib in Alopecia Areata.

N Engl J Med. 2022 May 5;386(18):1751-1752. doi: 10.1056/NEJMe2203440.

Oral Baricitinib Restores Hair Loss in Alopecia Areata.

JAMA. 2022 Jun 28;327(24):2386. doi: 10.1001/jama.2022.10378.

引用本文的文献

Recent Advances in Management of Vitiligo.

Indian J Dermatol. 2025 Jul-Aug;70(4):201-207. doi: 10.4103/ijd.ijd_158_25. Epub 2025 Jun 30.

Efficacy and Safety of JAK Inhibitors in the Management of Vitiligo: A Systematic Review and Meta-analysis.

Dermatol Ther (Heidelb). 2025 May 7. doi: 10.1007/s13555-025-01397-z.

Emerging Therapeutic Innovations for Vitiligo Treatment.

Curr Issues Mol Biol. 2025 Mar 14;47(3):191. doi: 10.3390/cimb47030191.

Unexpected Extensive Hair Whitening Following Baricitinib Treatment for Alopecia Universalis: A Case Report and Mechanistic Insights.

Cureus. 2024 Dec 23;16(12):e76287. doi: 10.7759/cureus.76287. eCollection 2024 Dec.

Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo: A Randomized Clinical Trial.

JAMA Dermatol. 2025 Apr 1;161(4):375-382. doi: 10.1001/jamadermatol.2024.5737.

Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study.

Clin Cosmet Investig Dermatol. 2024 Dec 18;17:2933-2944. doi: 10.2147/CCID.S501688. eCollection 2024.

Low-Dose Baricitinib Plus Narrow-Band Ultraviolet B for the Treatment of Progressive Non-Segmental Vitiligo: A Prospective, Controlled, Open-Label Study.

Pigment Cell Melanoma Res. 2025 Jan;38(1):e13209. doi: 10.1111/pcmr.13209. Epub 2024 Oct 23.

Up-and-Coming Drugs for the Treatment of Vitiligo.

Ann Dermatol. 2024 Aug;36(4):197-208. doi: 10.5021/ad.24.038.

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective.

Dermatol Reports. 2023 Sep 13;16(2):9839. doi: 10.4081/dr.2023.9839. eCollection 2024 Jun 14.

Rapid resolution of non-segmental vitiligo in a patient treated with abrocitinib: A case report.

SAGE Open Med Case Rep. 2024 Feb 14;12:2050313X241231527. doi: 10.1177/2050313X241231527. eCollection 2024.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Repigmentation of vitiligo with oral baricitinib.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Repigmentation of vitiligo with oral baricitinib.

作者信息

机构信息

出版信息

相似文献

引用本文的文献